Document Classification

Section Type: METHODS

Text: Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomised to receive either three cycles of 75mg/m (2) cisplatin plus 75mg/m (2) docetaxel, both administered on day 1 every 21days, followed by three cycles of 1, 200 mg/m (2) gemcitabine on days 1 and 8 every 3weeks (arm A), or three cycles of 25mg/m (2) cisplatin plus 25mg/m (2) docetaxel on days 1, 8 and 15 every 28days, followed by three cycles of 1, 200 mg/m (2) gemcitabine on days 1 and 8 every 3weeks (arm B).